Sebastian Kreiter

This inventor holds 27 USPTO granted patents and 15 published patent applications, plus 13 CIPO patents and 18 EPO patents, primarily in RNA Therapeutics. Top assignees: Biontech Se, Biontech Rna Pharmaceuticals Gmbh, Biontech Ag. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sebastian Kreiter. Retrieved from https://idiyas.com/inventor/sebastian-kreiter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 15)

% Patents Active = 100.0

CIPO Patents = 13 (Patent Applications = 7)

EPO Patents = 18 (Patent Applications = 27)

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 126(Granted Patents)

Company Filing History:

Biontech Rna Pharmaceuticals Gmbh

Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

patents

5. 5 out of 16

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

patents

6. 5 out of 25

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

patents

7. 2 out of 114

Universitãt Stuttgart

patents

8. 1 out of 1

Biontech Rna Pharmaceuticals Gbmh

patent

9. 1 out of 1

Biotech Rna Pharmaceuticals Gmbh

Tron-Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gg

patent

12. 1 out of 1

Tron-Translationale Onkologie an Der Universitätsmedzin Der Johannes Gutenberg-Universität Mainz Ggmbh

patent

13. 1 out of 1

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Gemeinnuzige Gmbh

patent

14. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Therapeutic RNA

Cytokine Encoding RNA

RNA Formulation

Immunotherapy

Recombinant Vaccines

Cancer Treatment

Autoimmune Diseases

Lipid Particle Formulations

Transcript Stability

T Cell Epitopes

Nucleic Acid Molecules

Immunogenic Epitopes

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12734233 - THERAPEUTIC RNA FOR HPV-POSITIVE CANCER (2026-09-15),

2. 12708643 - TREATMENT USING CYTOKINE ENCODING RNA (2026-08-18),

3. 12678497 - COMPOSITIONS COMPRISING NON-IMMUNOGENIC RNA ENCODING IMMUNOGENIC EPITOPES AND INTERFERON ALPHA (2026-07-14),

4. 12599660 - THERAPEUTIC RNA FOR HPV-POSITIVE CANCER (2026-04-14),

5. 12385049 - Modification of RNA, producing an increased transcript stability and translation efficiency (2025-08-12),

6. 12150947 - Formulation for administration of RNA (2024-11-26),

7. 11701413 - RNA for treatment of autoimmune diseases (2023-07-18),

8. 11660338 - Particles comprising a shell with RNA (2023-05-30),

9. 11559587 - RNA formulation for immunotherapy (2023-01-24),

10. 11337922 - Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell (2022-05-24),

11. 11318195 - Formulation for administration of RNA (2022-05-03),

12. 11298426 - Recombinant vaccines and use thereof (2022-04-12),

13. 11248264 - Individualized vaccines for cancer (2022-02-15),

14. 11156617 - Predicting T cell epitopes useful for vaccination (2021-10-26),

15. 11045418 - Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell (2021-06-29),

Title: Sebastian Kreiter: Advancing Therapeutics for Autoimmune Diseases

Introduction:

Sebastian Kreiter, a prominent inventor hailing from Mainz, Germany, has made significant contributions to the field of biomedical research. With numerous patents under his belt, Kreiter has been at the forefront of innovative solutions for the treatment of autoimmune diseases. This article shines a spotlight on his latest patents, career highlights, and collaborations.

Latest Patents:

Kreiter's latest patents demonstrate his groundbreaking work in developing RNA-based therapeutics for the treatment of autoimmune diseases. One of his notable patents involves the development of non-immunogenic RNA, which is instrumental in inducing tolerance towards autoantigens. This breakthrough paves the way for the development of therapeutic agents that can effectively address autoimmune conditions.

Additionally, Kreiter's recent patent focuses on the use of RNA decorated particles, particularly RNA decorated liposomes, for inducing an immune response. This invention showcases the potential of using pharmaceutical compositions comprising RNA decorated particles for prophylactic and therapeutic treatments involving specific antigens.

Career Highlights:

During his career, Kreiter has played a pivotal role in advancing scientific knowledge in the field of immunotherapy. Having worked with prestigious companies like BioNTech SE and BioNTech RNA Pharmaceuticals GmbH, he has consistently been at the forefront of cutting-edge research and development efforts.

Collaborations:

Kreiter's collaborations with renowned scientists and colleagues have further enhanced his contributions to the field. Notably, he has closely worked with Ugur Sahin and Mustafa Diken, prominent experts in the field of RNA-based therapeutics and immunotherapy. These collaborations have fostered a fertile environment for knowledge exchange and have laid the foundation for significant breakthroughs in the treatment of autoimmune diseases.

Conclusion:

Sebastian Kreiter's groundbreaking work in the development of RNA-based therapeutics has propelled the treatment of autoimmune diseases to new heights. His patents, focusing on non-immunogenic RNA and RNA decorated particles, have the potential to revolutionize the way we approach the prophylactic and therapeutic treatment of specific antigens. With a distinguished career and invaluable collaborations, Kreiter continues to push the boundaries of innovation in the field of medicine, providing hope for millions of people affected by autoimmune diseases worldwide.

Profile summary based on public USPTO records.